Tvardi Therapeutics, Inc.
TVRD
$3.98
$0.020.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.10% | -10.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.06% | 27.77% | |||
| Operating Income | 7.06% | -27.77% | |||
| Income Before Tax | 6.47% | -31.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.47% | -31.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.47% | -31.63% | |||
| EBIT | 7.06% | -27.77% | |||
| EBITDA | 7.09% | -27.88% | |||
| EPS Basic | 6.47% | -31.57% | |||
| Normalized Basic EPS | 6.48% | -31.57% | |||
| EPS Diluted | 6.47% | -31.44% | |||
| Normalized Diluted EPS | 6.48% | -31.57% | |||
| Average Basic Shares Outstanding | 0.01% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||